Nuvation Bio Reports New Patient Outcomes Data for Ibtrozi

Nuvation Bio announced new patient-reported outcomes data from the pivotal TRUST-II study of Ibtrozi - taletrectinib - in patients with advanced ROS1-positive non-small cell lung cancer, or NSCLC. The new data will be presented on May 31 at the ASCO Annual Meeting 2026. TRUST-II is a global Phase 2 study evaluating the safety and efficacy of IBTROZI in patients with advanced ROS1+ NSCLC. Mean changes from baseline improved or remained stable for most domains across both questionnaires. Quality-of-life and cognitive function scores improved from baseline or remained stable over time in both TKI-naive and TKI-pretreated patients. At the first assessment, 88% of patients reported improved or stable global health quality-of-life scores. The majority of patients in both subgroups improved or remained stable across subsequent time points throughout treatment. 84-96% of patients reported improved or stable scores for coughing and shortness of breath, and these improvements were sustained through eight months of treatment. In May 2026, the FDA accepted a supplemental New Drug Application with updated data for Ibtrozi with a target action date of January 4, 2027.